News & Updates

New drug applications approved by US FDA as of 01-15 January 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with percutaneous ethanol injection (PEI) appears to produce marked reductions in the volume of benign cystic thyroid nodules, with the reduction evident at 6 months post-treatment and stable over time, according to the results of a meta-analysis.

The vasodilator ifenprodil together with sorafenib has been identified as a new drug combination for hepatocellular carcinoma (HCC) treatment by researchers from the University of Hong Kong (HKU) using clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) screen.

Adding ibrutinib to obinutuzumab in the first-line setting sustains progression-free survival (PFS) benefit in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL), including patients with high-risk genomic features, according to the final analysis of the iLLUMINATE* trial.

In young- and middle-aged adults, haemorrhoidal disease more commonly arises in women, older people, ever-smokers, and hypertensives, reports a recent Korean study.

Non-O blood type appears to be a risk factor for cancer-associated venous thromboembolism (VTE), particularly in patients who have cancer types with low to intermediate thrombotic risk, according to data from the Cancer and Thrombosis Study (CATS) presented at ASH 2021.